Spotting the disease before it reveals its presence

Read time: 2 mins
3D Printed Protein /

A preclinical test that may open new perspectives in the diagnosis of neurological disorders. This is the result accomplished by a group of researchers from the Center of Complexity and Biosystems of the University of Milan, who just published their work on Physical Review Applied.

A vast class of incurable neurodegenerative disorders are characterized by the aggregation and deposition of aberrant proteins like the beta-amyloid peptide or the alfa-synuclein, considered to be a factor behind the development of Alzheimer’s and Parkinson’s diseases, respectively. Detecting the onset of such aggregations before the appearance of the symptoms of the disease is almost impossible nowadays, but some possible solutions have been proposed. One of the most promising ones is to take advantage of the same process that determines the spread of the diseases to amplify minute quantities of protein aggregates. By doing this, it would be possible to screen small biological samples for the presence of very low concentrations of aberrant aggregates, thus allowing preclinical diagnosis of neurodegenerative diseases.

Recent advances in microfluidic technology allow analysis of protein aggregation in very small samples but, in order to enable such diagnostic approach, it is necessary to find a way to minimize the risk of false positive or negative detections, which may easily occur when analysing small quantities of biological material.

And here is where the group of researchers from the Center of Complexity and Biosystems comes into play.

The authors of the study addressed the problem with a computational approach. Basically, they simulated the onset of protein aggregations in small samples, in order to study how this process fluctuates depending on the volume of the samples. By doing that, they managed to design and validate a preclinical screening test that will ultimately allow the determination of the exact number of aggregates within the analysed sample. Such a result will improve the precision and quality of protein aggregations detection, thus representing a first step towards the realization of in vitro tests for early diagnosis of neurodegenerative diseases.

“This is the first proof of concept in silico that could guide the development of a test in vitro to identify neurodegenerative disease before symptoms appear”, said Caterina la Porta, biologist and leader of the research group.

altri articoli

Nemmeno l'Europa prende la sufficienza in ambiente

L'Europa è il luogo dove ha preso avvio la Rivoluzione Industriale: una transizione epocale che ha catapultato l'intero pianeta verso una nuova epoca. In un battito di ciglia geologico l'umanità si è imposta come una forza globale capace di lasciare segni profondi e duraturi in tutti gli ecosistemi. Oggi la crisi climatica pone l'umanità di fronte alla necessità di una nuova transizione, ambientale, economica e sociale. Se in Europa questa transizione potrà davvero partire ed essere completata, potrà essere solo l'Europa stessa a deciderlo con le politiche che sceglierà di perseguire. Ma per ora, nonostante le ambizioni, la politica europea è troppo timida. Nell'immagine: cava di lignite a cielo aperto, Germania.

«Sebbene le politiche europee sull’ambiente e il clima abbiano contribuito a migliorare la situazione ambientale negli ultimi decenni, i progressi compiuti dall’Europa non sono sufficienti e le prospettive per l’ambiente nei prossimi dieci anni sono tutt’altro che rosee».